Z Squared ZSQR
NASDAQ ZSQR
$2.58 +0.28 (+11.96%)
At close: Nov 11, 2026 · 4:00 PM EST

Z Squared (ZSQR) Net Margin (2025 - 2026)

Updated

Z Squared (ZSQR) posted Net Margin of -866.60% for Q2 2026, down 866.57 percentage points from the prior quarter.

Analysis

Z Squared (ZSQR) Net Margin (2025 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Net Margin at Z Squared was -639.46%, up 12187.24 percentage points year-over-year; for FY2025, it came in at -874.29%.

  • Annual Net Margin shows a four-year change of +17058.08 percentage points (FY2021 to FY2025).
  • In prior years, Z Squared's Net Margin was -17932.37% in FY2021.
  • Quarterly Net Margin has run from a low of -5440.95% in Q1 2025 to a high of -0.03% in Q1 2026 over five years.
  • According to Business Quant data, Net Margin for the three prior quarters was -0.03% (Q1 2026), -146.48% (Q4 2025) and -1220.84% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 26.44%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 0.83%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 24.24%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 28.01%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 20.69%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 37.28%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 29.27%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 19.55%
10 Z Squared 121.90 Mn 95.14 Mn -1.77 Mn -866.60%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -866.60%
Mar 31, 2026 -0.03%
Dec 31, 2025 -146.48%
Sep 30, 2025 -1,220.84%
Mar 31, 2025 -5,440.95%
API Access

Z Squared Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=ZSQR&period=max&api_key=YOUR_API_KEY